A new trading day began on Tuesday, with Repligen Corp. (NASDAQ: RGEN) stock price up 0.59% from the previous day of trading, before settling in for the closing price of $163.58. RGEN’s price has ranged from $110.45 to $211.13 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 31.42%. Meanwhile, its annual earnings per share averaged -17.84%. With a float of $52.09 million, this company’s outstanding shares have now reached $55.77 million.
Considering the fact that the conglomerate employs 1783 people, you should pay attention to its efficiency factor.
Repligen Corp. (RGEN) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Medical Instruments & Supplies Industry. The insider ownership of Repligen Corp. is 7.00%, while institutional ownership is 99.62%. The most recent insider transaction that took place on Aug 02 ’24, was worth 1,139,040. Before that another transaction happened on Aug 02 ’24, when Company’s Senior VP, R&D sold 7,148 for $159.35, making the entire transaction worth $1,139,016. This insider now owns 12,288 shares in total.
Repligen Corp. (RGEN) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -17.84% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 14.71% during the next five years compared to 15.08% growth over the previous five years of trading.
Repligen Corp. (NASDAQ: RGEN) Trading Performance Indicators
Here are Repligen Corp.’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 5.56. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 15.30. Likewise, its price to free cash flow for the trailing twelve months is 77.28.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.04, a number that is poised to hit 0.34 in the next quarter and is forecasted to reach 1.91 in one year’s time.
Technical Analysis of Repligen Corp. (RGEN)
Compared to the last year’s volume of 0.64 million, its volume of 0.65 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 63.12%. Additionally, its Average True Range was 7.84.
During the past 100 days, Repligen Corp.’s (RGEN) raw stochastic average was set at 58.85%, which indicates a significant decrease from 81.94% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 69.09% in the past 14 days, which was higher than the 51.30% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $137.73, while its 200-day Moving Average is $164.83. Nevertheless, the first resistance level for the watch stands at $166.93 in the near term. At $169.33, the stock is likely to face the second major resistance level. The third major resistance level sits at $172.40. If the price goes on to break the first support level at $161.46, it is likely to go to the next support level at $158.39. Should the price break the second support level, the third support level stands at $155.99.
Repligen Corp. (NASDAQ: RGEN) Key Stats
With a market capitalization of 9.22 billion, the company has a total of 55,876K Shares Outstanding. Currently, annual sales are 638,760 K while annual income is 41,580 K. The company’s previous quarter sales were 154,070 K while its latest quarter income was 3,320 K.
